The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with all features of the metabolic syndrome. Although deposition of excess triglycerides within liver cells, a hallmark of NAFLD, is associated with a loss of insulin sensitivity, it is not clear which cellular abnormality arises first. We have explored this in mice overexpressing carbohydrate responsive element-binding protein (ChREBP). On a standard diet, mice overexpressing ChREBP remained insulin sensitive, despite increased expression of genes involved in lipogenesis/fatty acid esterification and resultant hepatic steatosis (simple fatty liver). Lipidomic analysis revealed that the steatosis was associated with increased accumulation of monounsaturated fatty acids (MUFAs). In primary cultures of mouse hepatocytes, ChREBP overexpression induced expression of stearoyl-CoA desaturase 1 (Scd1), the enzyme responsible for the conversion of saturated fatty acids (SFAs) into MUFAs. SFA impairment of insulin-responsive Akt phosphorylation was therefore rescued by the elevation of Scd1 levels upon ChREBP overexpression, whereas pharmacological or shRNA-mediated reduction of Scd1 activity decreased the beneficial effect of ChREBP on Akt phosphorylation. Importantly, ChREBP-overexpressing mice fed a high-fat diet showed normal insulin levels and improved insulin signaling and glucose tolerance compared with controls, despite having greater hepatic steatosis. Finally, ChREBP expression in liver biopsies from patients with nonalcoholic steatohepatitis was increased when steatosis was greater than 50% and decreased in the presence of severe insulin resistance. Together, these results demonstrate that increased ChREBP can dissociate hepatic steatosis from insulin resistance, with beneficial effects on both glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In this regard, ChREBP expression in liver biopsies from patients with MASH was observed to be two-fold higher when the histologic steatosis score was greater than 50% compared to those with less than 50%.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
The cited source says what the claim attributes to it.
In the citing paper
“However, it decreased in the presence of severe IR [34,94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Transient overexpression of ChREBP in the liver results in hepatic steatosis without IR through induction of the lipogenic enzyme SCD1, suggesting that increased ChREBP can dissociate hepatic steatosis from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
In the citing paper
“Taken together, these findings demonstrate that ChREBP-driven hepatic steatosis can be dissociated from IR [94].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 1×
“genes was achieved by the ΔΔCt method (88).”
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“(91): 0, absent; 1, <5%; 2, 5%–33%; 3, 33%–66%; 4, >66%.”
Signal integration in the endoplasmic reticulum unfolded protein response
Ron, D., & Walter, P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2199 · Cited by 6,296 · cited 1×
“UPR induces transcription of a set of genes whose protein products increase the capacity for protein folding and ER-associated degradation and induces apoptosis when the ER function is severely impaired (41, 42).”
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 11×
“To our knowledge, our work is the first to report that hepatic ChREBP expression varies positively according to the degree of steatosis and inversely to insulin resistance in a cohort of patients with NASH.”
InfluentialDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 5×
“Using a multiple-stable-isotope approach, Don-nelly et al. (16) estimated that, of the TG content accounted for in the livers of patients with NAFLD, 60% arose from NEFA, a little over 10% came from the diet, and close to 30% came from de novo lipogenesis, underlying the importance of de novo TG synthesis in the etiol…”
InfluentialNutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Nonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Ory, D. S., & Schaffer, J. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630588100 · Cited by 2,075 · cited 17×
“Recent studies have revealed that chronic SFA exposure activates unfolded protein response (UPR) in cultured cells (39, 40).”
InfluentialPGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624 · cited 1×
“In the liver, SIRT1 controls gluconeogenic activity by modulating the acetylation levels of a network of transcription factors and/or coactivators, including PPARGC1A (74–76).”
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495 · cited 1×
“We also measured the expression of fibroblast growth factor 21 (FGF21), a key metabolic regulator whose expression is regulated via PPAR pathways during states requiring increased fatty acid oxidation (33).”
Research works printed but not linked: 2
- Denechaud, 2008, J Clin Invest., 118, 956
- Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes . 2006;55(8):2159-2170. · DOI · Paper page
Cited by
Items 101–200 of 405
Differences in Muscle Transcriptome among Pigs Phenotypically Extreme for Fatty Acid Composition
Puig-Oliveras, A., Ramayo‐Caldas, Y., Corominas, J., Estellé, J., Pérez-Montarelo, D., Hudson, N. J., Casellas, J., Folch, J. M., & Ballester, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099720 · Cited by 114
Reichold, A., Brenner, S. A., Spruss, A., Förster‐Fromme, K., Bergheim, I., & Bischoff, S. C. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.09.011 · Cited by 84
“011 development of NAFLD/NASH is associated with the development of insulin resistance and cardiovascular disease, further emphasizing the relevance of these diseases [11,12].”
BackgroundPhysiological Suppression of Lipotoxic Liver Damage by Complementary Actions of HDAC3 and SCAP/SREBP
Papazyan, R., Sun, Z., Kim, Y. H., Titchenell, P. M., Hill, D. A., Lu, W., Damle, M., Wan, M., Zhang, Y., Briggs, E. R., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.012 · Cited by 76
“Although it was possible that glucose stimulation of ChREBP-induced lipogenesis contributed to the increased viability (Benhamed et al., 2012), we did not detect an increase in the expression of Fasn or other DNL factors in this cohort (Figure S6B).”
BackgroundCDK4 is an essential insulin effector in adipocytes
Lagarrigue, S., Lopez-Mejia, I. C., Denechaud, P.-D., Escoté, X., Castillo-Armengol, J., Jimenez, V., Chavey, C., Giralt, A., Lai, Q., Zhang, L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81480 · Cited by 76
Self-citationRetractedReappraisal of the optimal fasting time for insulin tolerance tests in mice
Carper, D. A., Coué, M., Laurens, C., Langin, D., & Moro, C. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101058 · Cited by 84
“Other investigators used empirically shorter fasting times (2e5 h) [9,10].”
MethodDysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
Bhat, N., & Mani, A. (2023) · Nutrients · doi:10.3390/nu15102323 · Cited by 92
“Increased levels of glycolytic intermediates such as glucose 6-phosphate, fructose, and the pentose phosphate pathway intermediate xylulose-5-phosphate activate the transcription factors carbohydrate response element binding protein 1a (ChRebp1a) and ChRebp1b [85,90,92–94].”
BackgroundSingle-nucleus RNA-seq2 reveals functional crosstalk between liver zonation and ploidy
Richter, M. L., Deligiannis, I. K., Yin, K., Danese, A., Lleshi, E., Coupland, P., Vallejos, C. A., Matchett, K. P., Henderson, N. C., Colome-Tatche, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24543-5 · Cited by 75
Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG
Chen, J., Zhou, Y., Liu, Z., Lu, Y. H., Jiang, Y., Cao, K., Zhou, N., Wang, D., Zhang, C., Zhou, N., et al. (2024) · Science · doi:10.1126/science.adi3332 · Cited by 85
Ducheix, S., Montagner, A., Théodorou, V., Ferrier, L., & Guillou, H. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.03.016 · Cited by 86
Self-citationFructose drives de novo lipogenesis affecting metabolic health
Geidl, B., & Gerber, P. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0270 · Cited by 103
Pleiotropic Effects of Lipid Genes on Plasma Glucose, HbA1c, and HOMA-IR Levels
Li, N., van der Sijde, M. R., LifeLines Cohort Study Group, Bakker, S. J. L., Dullaart, R. P. F., van der Harst, P., Gansevoort, R. T., Elbers, C. C., Wijmenga, C., Snieder, H., et al. (2014) · Diabetes · doi:10.2337/db13-1800 · Cited by 71
“A mouse experiment has shown that MLXIPL overexpression in liver can dissociate hepatic steatosis from glucose intolerance, depending on obese background or diet (30), whereas knockdown of MLXIPL in mice can improve hypertriglyceridemia (31).”
BackgroundAdipocyte browning and resistance to obesity in mice is induced by expression of ATF3
Cheng, C., Ku, H., Cheng, J., Chao, S.-W., Li, H., Lai, P., Chang, C., Don, M., Chen, H.-H., & Lin, H. (2019) · Communications Biology · doi:10.1038/s42003-019-0624-y · Cited by 85
Marmier, S., Dentin, R., Daujat‐Chavanieu, M., Guillou, H., Bertrand‐Michel, J., Gerbal‐Chaloin, S., Girard, J., Lotersztajn, S., & Postic, C. (2015) · Hepatology · doi:10.1002/hep.27778 · Cited by 71
“Indeed, lipidomics analysis revealed a specific lipogenic signature with a significant increase in SCD1 activity.(23)”
BackgroundMethodSelf-citationHepatic menin recruits SIRT1 to control liver steatosis through histone deacetylation
Cao, Y., Xue, Y., Xue, L., Jiang, X., Wang, X., Zhang, Z., Yang, J., Lu, J., Zhang, C. X., Wang, W., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.011 · Cited by 75
“It supports the concept and conclusions of recent studies [37,38].”
BackgroundResultShearn, C. T., Smathers, R. L., Backos, D. S., Reigan, P., Orlicky, D. J., & Petersen, D. R. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.011 · Cited by 69
“ChREBP has been proposed to link gluconeogenesis and lipogenesis via to Akt phosphorylation [38, 39].”
BackgroundThe Glucose Sensor ChREBP Links De Novo Lipogenesis to PPARγ Activity and Adipocyte Differentiation
Witte, N., Muenzner, M., Rietscher, J., Knauer, M., Heidenreich, S., Nuotio-Antar, A. M., Graef, F. A., Fedders, R., Tolkachov, A., Göhring, I., et al. (2015) · Endocrinology · doi:10.1210/en.2015-1209 · Cited by 77
“Although ChREBP mutants have been proven useful tools for studying its molecular function (8), dissecting the physiological activation of ChREBP by glucose metabolites in regard to this new mechanism would be interesting.”
Background1-Deoxynojirimycin Alleviates Liver Injury and Improves Hepatic Glucose Metabolism in db/db Mice
Liu, Q., Li, X., Li, C., Zheng, Y., Wang, F., Li, H., & Peng, G. (2016) · Molecules · doi:10.3390/molecules21030279 · Cited by 72
Regulation of hepatic lipogenesis by the zinc finger protein Zbtb20
Liu, G., Zhou, L., Zhang, H., Chen, R., Zhang, Y., Li, L., Lu, J.-Y., Jiang, H., Liu, D., Qi, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14824 · Cited by 73
“Our results demonstrate that ZBTB20 governs hepatic lipogenesis largely through ChREBPs, with no significant effects on SREBP1c expression or activity.”
InfluentialLipid homeostasis in diabetic kidney disease
Wang, Y., Liu, T., Wu, Y., Wang, L., Ding, S., Hou, B., Zhao, H., Liu, W., & Li, P. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.95216 · Cited by 85
“ChREBP regulates the expression of ACC and FAS and regulates adipogenesis by inducing expression of the glycolytic enzyme pyruvate kinase 1 [55].”
BackgroundMouse KLF11 regulates hepatic lipid metabolism
Zhang, H., Chen, Q., Yang, M. H., Zhu, B., Cui, Y., Xue, Y., Gong, N., Cui, A., Wang, M., Shen, L., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.024 · Cited by 73
Activated Kupffer cells inhibit insulin sensitivity in obese mice
Tencerova, M., Aouadi, M., Vangala, P., Nicoloro, S. M., Yawe, J. C., Cohen, J. L., Shen, Y., Garcia‐Menendez, L., Pedersen, D. J., Gallagher‐Dorval, K., et al. (2015) · The FASEB Journal · doi:10.1096/fj.15-270496 · Cited by 65
“Furthermore, Nf-kb has been shown to be significantly decreased inmice overexpressing carbohydrate response element binding protein (Chrebp) in hepatocytes, which also exhibit an increasedhepatic steatosis but improvedglucosemetabolism in the liver (33).”
BackgroundResultDuan, X., Meng, Q., Wang, C., Liu, Z., Liu, Q., Sun, H., Sun, P., Yang, X., Huo, X., Peng, J., et al. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.12.006 · Cited by 66
The Impact of High-Fat Diet on Metabolism and Immune Defense in Small Intestine Mucosa
Wiśniewski, J. R., Friedrich, A., Keller, T., Mann, M., & Koepsell, H. (2015) · Journal of Proteome Research · doi:10.1021/pr500833v · Cited by 64
Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD
Allison, M., Griffin, J., Vacca, M., & Vidal-Puig, A. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562945 · Cited by 63
Fructose impairs fat oxidation: Implications for the mechanism of western diet-induced NAFLD
Inci, M. K., Park, S., Helsley, R. N., Attia, S. L., & Softic, S. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.109224 · Cited by 69
Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation
Castaño, D., Larequi, E., Belza, I., Astudillo, A. M., Martínez‐Ansó, E., Balsinde, J., Argemí, J., Aragón, T., Moreno-Aliaga, M. J., Muntané, J., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.012 · Cited by 65
“However, it is not known whether accumulation of TG or other lipid compounds causes hepatic insulin resistance or whether the latter is responsible for the development of hepatic steatosis [4].”
BackgroundHave guidelines addressing physical activity been established in nonalcoholic fatty liver disease?
Finelli, C. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i46.6790 · Cited by 62
MondoA/ChREBP: The usual suspects of transcriptional glucose sensing; Implication in pathophysiology
Richards, P., Ourabah, S., Montagne, J., Burnol, A., Postic, C., & Guilmeau, S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.033 · Cited by 69
Self-citationMetabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions
Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.029 · Cited by 61
Ceja-Galicia, Z. A., Cespedes-Acuña, C. L. A., & El-Hafidi, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020788 · Cited by 61
Wolf, D., Jehle, F., Michel, N. A., Bukosza, É. N., Rivera, J., Chen, Y., Hoppe, N., Dufner, B., Rodríguez, A. O., Colberg, C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.008055 · Cited by 67
“It is also challenging to explore how CD40 dissects increased hepatic steatosis from normal hepatic insulin resistance, but elevated expression of the transcription factor ChREBP may be a key as previously postulated.(39) Targeting CD40 has the potential of modulating various human diseases.”
BackgroundRecent progress on the role of ChREBP in glucose and lipid metabolism [Review]
Iizuka, K. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0121 · Cited by 76
Bartok, O., Teesalu, M., Ashwal-Fluss, R., Pandey, V., Hanan, M., Rovenko, B. M., Poukkula, M., Havula, E., Moussaieff, A., Vodala, S., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201591385 · Cited by 64
“In humans, altered ChREBP activity in adipose tissue and liver is associated with severe obesity and polymorphisms of chrebp are linked to elevated circulating triglyceride levels (Kooner et al , 2008; Benhamed et al , 2012; Eissing et al , 2013).”
Jois, T., Chen, W., Howard, V., Harvey, R., Youngs, K., Thalmann, C., Saha, P., Chan, L., Cowley, M. A., & Sleeman, M. W. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.07.006 · Cited by 60
Adaptive and maladaptive roles for ChREBP in the liver and pancreatic islets
Katz, L. S., Baumel-Alterzon, S., Scott, D. K., & Herman, M. A. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100623 · Cited by 62
Long, F., Bhatti, M. R., Kellenberger, A., Sun, W., Modica, S., Höring, M., Liebisch, G., Krieger, J.-P., Wolfrum, C., & Challa, T. D. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101675 · Cited by 72
Helsley, R. N., Park, S., Vekaria, H. J., Sullivan, P. G., Conroy, L. R., Sun, R. C., Romero, M. D. M., Herrero, L., Bons, J., King, C. D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.010 · Cited by 61
Agius, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.019 · Cited by 62
Ju, H., Chung, J. H., Hwang, J. W., Kim, O. Y., Lee, J.-Y., & Shin, M. (2014) · Food and Chemical Toxicology · doi:10.1016/j.fct.2014.11.001 · Cited by 57
Tryndyak, V., de Conti, A., Kobets, T., Kutanzi, K., Koturbash, I., Han, T., Fuscoe, J. C., Latendresse, J. R., Melnyk, S., Shymonyak, S., et al. (2012) · The FASEB Journal · doi:10.1096/fj.12-209569 · Cited by 57
“Likewise, a decreased expression of ChREBP has been found in patients with NASH with severe insulin resistance (43).”
BackgroundJiang, S., Yang, X., Yang, Z., Li, J., Xu, M., Qu, Y.-X., Tang, J., Li, Y., Wang, L., Shao, Y., et al. (2022) · Hepatology · doi:10.1002/hep.32381 · Cited by 61
Yang, Y., Li, W., Liu, Y., Yan, L., Gao, L., & Zhao, J. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.64 · Cited by 60
Ansari, R. A., Husain, K. M., & Rizvi, S. A. A. (2016) · Biomolecules · doi:10.3390/biom6030029 · Cited by 61
“Its roles in non-alcoholic fatty liver disease (NAFLD), which parallels alcoholic fatty liver, is implicated in transcriptional activation of lipogenic genes, such as FAS, ACC and liver pyruvate kinase [84,85].”
BackgroundIntegration of ChREBP-Mediated Glucose Sensing into Whole Body Metabolism
Baraille, F., Planchais, J., Dentin, R., Guilmeau, S., & Postic, C. (2015) · Physiology · doi:10.1152/physiol.00016.2015 · Cited by 55
“Indeed, the study reports that the specific rise in monounsaturated fatty acids, lipid products of the SCD1, target of ChREBP, was instrumental in this dissociation (3).”
BackgroundSelf-citationDiabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
NCoR1 and SMRT Play Unique Roles in Thyroid Hormone Action In Vivo
Shimizu, H., Astapova, I., Ye, F., Bilban, M., Cohen, R. N., & Hollenberg, A. N. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01208-14 · Cited by 54
“To try to understand how the lipogenic process was being activated in the absence of corepressor function, we examined the expression of ChREBP, which is a known TR target and whose hepatic overexpression leads to a phenotype that is very similar to that present in L-DKO mice (31).”
BackgroundResultHCF-1 Regulates De Novo Lipogenesis through a Nutrient-Sensitive Complex with ChREBP
Lane, E. A., Choi, D. W., García-Haro, L., Levine, Z. G., Tedoldi, M., Walker, S., & Danial, N. N. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.019 · Cited by 64
“The capacity to regulate both fatty acid oxidation and synthesis argues for a potentially broader role of HCF-1 in hepatic substrate metabolism and warrants future investigation of its significance in systemic physiology and in NAFLD.”
InfluentialHuman-based systems: Mechanistic NASH modelling just around the corner?
Boeckmans, J., Natale, A., Buyl, K., Rogiers, V., De Kock, J., Vanhaecke, T., & Rodrigues, R. M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.029 · Cited by 53
Azzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52
“Overall, an enhanced remodelling of the lipidome toward desaturated lipids is expected to reduce lipotoxicity in murine models of NASH [28]; accordingly, the Insig1 KO mice showed reduced hepatocyte damage with ALT values below the upper limit of normal (Figure S2P) which, although “clinically” significant, did not re…”
BackgroundE2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver
Lai, Q., Giralt, A., Le May, C., Zhang, L., Cariou, B., Denechaud, P.-D., & Fajas, L. (2017) · JCI Insight · doi:10.1172/jci.insight.89729 · Cited by 52
Self-citationNURR1 activation in skeletal muscle controls systemic energy homeostasis
Amoasii, L., Sanchez‐Ortiz, E., Fujikawa, T., Elmquist, J. K., Bassel‐Duby, R., & Olson, E. N. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902490116 · Cited by 51
From Food to Genes: Transcriptional Regulation of Metabolism by Lipids and Carbohydrates
Bravo-Ruiz, I., Medina, M. Á., & Martínez-Poveda, B. (2021) · Nutrients · doi:10.3390/nu13051513 · Cited by 62
“This has been verified by lipidomic studies showing an increase in unsaturated fatty acids in hepatic steatosis, a condition where there is also an increase in the expression of ChREBP [135].”
BackgroundInfluentialEpigenetics and Beyond: Targeting Histone Methylation to Treat Type 2 Diabetes Mellitus
Yang, Y., Luan, Y., Feng, Q., Chen, X., Qin, B., Ren, K., & Luan, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.807413 · Cited by 59
Ashworth, W. B., Davies, N. A., & Bogle, I. D. L. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005105 · Cited by 55
“Alternatively, it is possible that SREBP-1c is instead stimulated by hyperglycaemia or by the fats themselves [13, 92], similar to the effects of carbohydrate responsive element binding protein (ChREBP) [32].”
BackgroundTranscriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 58
“ChREBP Humans, mice Lipid metabolism Upregulation [22]”
BackgroundInfluentialLi, W., Li, Y., Wang, Q., & Yang, Y. (2014) · BioMed Research International · doi:10.1155/2014/196198 · Cited by 65
“Primers for SREBP-1c, ACC, FAS, CPT-1α, and CD36 were previously described [15].”
Rajas, F., Labrune, P., & Mithieux, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.002 · Cited by 60
“[39] Grefhorst A, Schreurs M, Oosterveer MH, Cortes VA, Havinga R, Herling AW, et al. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor alpha (LXRalpha) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1.”
BackgroundInfluentialDietary oleic acid regulates hepatic lipogenesis through a liver X receptor-dependent signaling
Ducheix, S., Montagner, A., Polizzi, A., Lasserre, F., Régnier, M., Marmugi, A., Benhamed, F., Bertrand-Michel, J., Mselli-Lakhal, L., Loiseau, N., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181393 · Cited by 50
“Therefore, pharmacological activation of LXR leads to hepatic neutral lipid accumulation that is the hallmark of NAFLD [21].”
BackgroundInfluentialSelf-citationLiver and insulin resistance: New wine in old bottle!!!
Patel, B. M., & Goyal, R. K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172657 · Cited by 54
Targeting Stearoyl-CoA Desaturase in Solid Tumors
Kubota, C. S., & Espenshade, P. J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4044 · Cited by 67
Nuotio-Antar, A. M., Poungvarin, N., Li, M., Schupp, M., Mohammad, M. A., Gerard, S., Zou, F., & Chan, L. (2015) · Endocrinology · doi:10.1210/en.2015-1210 · Cited by 50
Retinol saturase coordinates liver metabolism by regulating ChREBP activity
Heidenreich, S., Witte, N., Weber, P., Göhring, I., Tolkachov, A., von Loeffelholz, C., Döcke, S., Bauer, M. W., Stockmann, M., Pfeiffer, A. F. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00430-w · Cited by 56
Zhang, S., Guo, F., Yu, M., Yang, X., Yao, Z., Li, Q., Wei, Z., Feng, K., Zeng, P., Zhao, D., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.034 · Cited by 49
Mertens, J., Block, C. E. M. D., Spinhoven, M. J., Driessen, A. L. C., Francque, S., & Kwanten, W. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768576 · Cited by 54
“Therefore, both SREBPs and ChREBP are potential pivotal contributors to fatty liver disease in T1D and insulin-dependent T2D (Regnell and Lernmark, 2011; Benhamed et al., 2012).”
BackgroundVerdú, E., Homs, J., & Boadas‐Vaello, P. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182413333 · Cited by 70
Ortega‐Azorín, C., Sorlí, J. V., Estruch, R., Asensio, E. M., Coltell, Ó., González, J. I., Martínez‐González, M. Á., Ros, E., Salas‐Salvadó, J., Fitó, M., et al. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000301 · Cited by 53
“Although the genome-wide association study and meta-analyses have consistently found a significant association between the minor allele and lower triglyceride concentrations,(6,11,13,14) other experimental approaches have not shown the same consistency, which may be because of the fact that the expression of this gene…”
ResultAkinrotimi, O., Riessen, R., VanDuyne, P., Park, J. E., Lee, Y., Wong, L., Zavacki, A. M., Schoonjans, K., & Anakk, S. (2017) · Hepatology · doi:10.1002/hep.29305 · Cited by 51
“Interestingly, overexpression of Chrebp-b has been shown to promote HS and Pepck overexpression causes IR.”
BackgroundInfluentialBakuchiol Contributes to the Hepatotoxicity ofPsoralea corylifoliain Rats
Li, Z., Abulizi, A., Zhao, G., Wang, T., Zhou, F., Jiang, Z., Aibai, S., & Zhang, L. (2017) · Phytotherapy Research · doi:10.1002/ptr.5851 · Cited by 51
“To a large extent, TG is controlled by the level of transcription by PPARα (Benhamed et al., 2012; Lavoie and Pighon, 2012).”
BackgroundHatchwell, L., Harney, D. J., Cielesh, M., Young, K., Koay, Y. C., O’Sullivan, J. F., & Larance, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.051 · Cited by 45
Komori, T., Tanaka, M., Senba, E., Miyajima, A., & Morikawa, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.542399 · Cited by 44
“Of course, we cannot rule out the possibility that other pathways may induce de novo lipogenesis in the liver, including glucose-induced carbohydrate response element-binding protein activation (49) and/or cholesterol-induced liver X receptor activation (50).”
BackgroundArtemisia annua Leaf Extract Attenuates Hepatic Steatosis and Inflammation in High-Fat Diet-Fed Mice
Kim, K. E., Ko, K., Heo, R. W., Yi, C., Shin, H. J., Kim, J. Y., Park, J. H., Nam, S., Kim, H., & Roh, G. S. (2016) · Journal of Medicinal Food · doi:10.1089/jmf.2015.3527 · Cited by 44
“However, adenoviral induced ChREBP-overexpressing mice fed an HFD have better glucose tolerance, despite increased hepatic steatosis; furthermore, ChREBP expression is positively related to the degree of steatosis and inversely to insulin resistance in patients with NASH.(31) Our data showed that ChREBP expression was…”
BackgroundPPP2R5C couples hepatic glucose and lipid homeostasis
Cheng, Y.-S., Seibert, O., Klöting, N., Dietrich, A., Straßburger, K., Fernández-Veledo, S., Vendrell, J. J., Zorzano, A., Blüher, M., Herzig, S., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005561 · Cited by 43
“We did observe an increase in expression of G6PC (S2H Fig), which is a ChREBP target [31], as discussed below.”
BackgroundChandrasekaran, P., Weiskirchen, S., & Weiskirchen, R. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30579 · Cited by 49
“12,13 As a result, these pathways become dysregulated or impaired, leading to an accumulation of lipid droplets in hepatocytes and an increase in PLIN proteins.”
BackgroundChREBP Regulates Itself and Metabolic Genes Implicated in Lipid Accumulation in β–Cell Line
Sae‐Lee, C., Moolsuwan, K., Chan, L., & Poungvarin, N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147411 · Cited by 51
“Overexpression of ChREBP in liver induces the expression of Pklr, Fasn, Acaca, stearoyl-CoA desaturase-1 (Scd1), and ELOVL fatty acid elongase 6 (Elovl6), modifying lipid composition in the process [27].”
BackgroundGu, L., Zhu, Y., Watari, K., Lee, M., Liu, J., Perez, S., Thai, M., Mayfield, J. E., Zhang, B., Rocha, K. C. E., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.021 · Cited by 46
Matikainen, N., Adiels, M., Söderlund, S., Stennabb, S., Ahola, T., Hakkarainen, A., Borén, J., & Taskinen, M. (2014) · Obesity · doi:10.1002/oby.20781 · Cited by 42
“This is in line with reports indicating that increased hepatic DNL associates with an atherogenic dyslipidemia and insulin resistance (28,29).”
ResultSahini, N., Selvaraj, S., & Borlak, J. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114085 · Cited by 42
“mice/human liver The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans real time qRT-PCR [53] Hepatic steatosis”
BackgroundSahini, N., & Borlak, J. T. (2016) · Translational research · doi:10.1016/j.trsl.2016.06.003 · Cited by 45
Curcumin and dietary polyphenol research: beyond drug discovery
Jin, T. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.179 · Cited by 45
Sesamol Alleviates Obesity-Related Hepatic Steatosis via Activating Hepatic PKA Pathway
Xu, H., Yu, L., Chen, J., Yang, L., Lin, C., Shi, X., & Qin, H. (2020) · Nutrients · doi:10.3390/nu12020329 · Cited by 42
“Hepatic steatosis is the main pathological feature of NAFLD and the key cause of more severe and progressive disease [5].”
BackgroundLei, Y., Hoogerland, J. A., Bloks, V. W., Bos, T., Bleeker, A., Wolters, H., Wolters, J. C., Hijmans, B. S., van Dijk, T. H., Thomas, R., et al. (2020) · Hepatology · doi:10.1002/hep.31198 · Cited by 41
ChREBP Reciprocally Regulates Liver and Plasma Triacylglycerol Levels in Different Manners
Iizuka, K., Takao, K., Kato, T., Horikawa, Y., & Takeda, J. (2018) · Nutrients · doi:10.3390/nu10111699 · Cited by 43
“Consistent with a previous paper [33], we confirmed that ChREBP overexpression increased hepatic triglyceride contents, altered hepatic lipid composition, and lowered plasma glucose levels.”
BackgroundResultInfluentialNonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter
Chiriac, S. A., Stanciu, C., Gîrleanu, I., Cojocariu, C., Sfarti, C. V., Sîngeap, A.-M., Cuciureanu, T., Huiban, L., Muzica, C. M., Zenovia, S., et al. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/6696857 · Cited by 56
The Potential Roles of Artemisinin and Its Derivatives in the Treatment of Type 2 Diabetes Mellitus
Jiang, Y., Shui, J., Zhang, B., Chin, J.-W., & Yue, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585487 · Cited by 48
“, 2015) and carbohydrate-responsive element-binding protein (ChREBP) in both ob/ob mice and HFD mice indicated the overproduction of glucose (Benhamed et al., 2012; AbdulWahed et al., 2017).”
BackgroundSassu, E. D., McDermott, J. E., Keys, B. J., Esmaeili, M., Keene, A. C., Birnbaum, M. J., & DiAngelo, J. R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.08.028 · Cited by 46
“In response to high glucose conditions, ChREBP translocates into the nucleus, where it activates the expression of pyruvate kinase and many lipogenic enzymes, including fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), and ATP citrate lyase (ATPCL), ultimately leading to increased fat accumulation [2,3].”
Kim, G., Lee, Y., Kwon, J. H., Cho, J., Pan, C., Starost, M. F., Mansfield, B. C., & CHOU, J. Y. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.01.003 · Cited by 44
“Studies have shown that mice over-expressing hepatic ChREBP exhibit improved glucose tolerance compared to controls [21].”
Fat and carbohydrate in western diet contribute differently to hepatic lipid accumulation
Wu, W., Tsuchida, H., Kato, T., Niwa, H., Horikawa, Y., Takeda, J., & Iizuka, K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.092 · Cited by 40
Thyroid hormone signaling promotes hepatic lipogenesis through the transcription factor ChREBP
Mendoza, A., Tang, C. J., Choi, J., Acuña, M., Logan, M., Martin, A. G., Al-Sowaimel, L., Desai, B. N., Tenen, D. E., Jacobs, C. L., et al. (2021) · Science Signaling · doi:10.1126/scisignal.abh3839 · Cited by 45
E2F1 promotes hepatic gluconeogenesis and contributes to hyperglycemia during diabetes
Giralt, A., Denechaud, P., López‐Mejía, I. C., Delacuisine, B., Blanchet, É., Bonner, C., Pattou, F. N., Annicotte, J., & Fajas, L. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.02.011 · Cited by 42
“Primary hepatocytes were isolated as previously described [14].”
MethodSelf-citationOptimal fasting duration for mice as assessed by metabolic status
Fu, J., Liu, S., Li, M., Guo, F., Wu, X., Hu, J., Wen, L., Wang, J., & Li, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-72695-3 · Cited by 48
HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis
Sargsyan, A., Doridot, L., Hannou, S. A., Tong, W., Srinivasan, H., Ivison, R., Monn, R., Kou, H. H., Haldeman, J. M., Arlotto, M. E., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.153740 · Cited by 38
Distinct mTORC1 pathways for transcription and cleavage of SREBP-1c
Quinn, W. J., & Birnbaum, M. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214113109 · Cited by 38
“Two transcription factors coordinate the expression of genes encoding lipogeneic enzymes: carbohydrate responsive elementbinding protein 1 (ChREBP1), which is regulated by metabolites of glucose, and sterol regulatory element-binding protein 1c (SREBP-1c), whose activity is enhanced by insulin and amino acids working…”
BackgroundO-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing
Benhamed, F., Filhoulaud, G., Caron, S., Lefèbvre, P., Staels, B., & Postic, C. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00230 · Cited by 43
“The mirror experiment in which the ChREBP protein was overexpressed through an adenoviral approach in liver of mice led to an exacerbation of the glycolysis and lipogenesis pathways associated with the development of hepatic steatosis (27).”
Self-citationXu, E., Forest, M., Schwab, M. G., Avramoglu, R. K., St-Amand, E., Caron, A. Z., Bellmann, K., Shum, M., Voisin, G., Paquet, M., et al. (2013) · Hepatology · doi:10.1002/hep.26957 · Cited by 43
“We also assessed ChREBP activity since this lipogenic transcription factor has previously been shown to dissociate hepatic steatosis from insulin resistance in both mouse and human subjects.(21) The hepatic activity of ChREBP was significantly higher in Ptpn6 livers as compared to Ptpn6 livers from 16-week HFD-fed mic…”
BackgroundResultRabbani, N., & Thornalley, P. J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1268308 · Cited by 44
Revisited guidelines for metabolic tolerance tests in mice
Moro, C., & Magnan, C. (2024) · Lab Animal · doi:10.1038/s41684-024-01473-5 · Cited by 49
Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 37
“41 39,42 e 46 The liver-speci fi c deletion of ACC1 decreases the hepatic lipids content and the DNL , although mice are not completely protected from hepatic steatosis because a compensatory up-regulation of ACC2 which inhibits the b -oxida- tion.”
Luque, G. M., Lopez‐Vicchi, F., Ornstein, A. M., Brie, B., Winne, C. D., Fiore, E. J., Millan, M. I. P., Mazzolini, G. D., Rubinstein, M., & Becú‐Villalobos, D. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00200.2016 · Cited by 33
“steatosis (6), and high levels of liver Chrebp are found in obese mice (63).”
BackgroundThe Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma
Zhang, C., & Yang, M. J. (2021) · Cancers · doi:10.3390/cancers13153740 · Cited by 37
YANG, Z. K., Zhang, H., Niu, Y., Zhang, W., Zhu, L., Li, X., Lü, S., Fan, J., Li, X., Ning, G., et al. (2016) · Scientific Reports · doi:10.1038/srep37886 · Cited by 33
Metadata
- Authors
- Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., Girard, J., Guillou, H., & Postic, C.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital Saint-Antoine (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Pitié-Salpêtrière Hospital (FR)
- Toxicologie Alimentaire (FR)
- Institut Cochin (FR)
- Corresponding author
- Postic, Catherine
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2012-06-01
- Volume
- 122
- Issue
- 6
- Pages
- 2176-2194
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3366390
- OpenAlex
- W2117220292
- Cited by
- 408
- References
- 94
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 22 · 2023: 35 · 2022: 27 · 2021: 28 · 2020: 34 · 2019: 23 · 2018: 25 · 2017: 35 · 2016: 27 · 2015: 30 · 2014: 41 · 2013: 27 · 2012: 13
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- HAL Portal Artxiker (Hindustan Aeronautics Limited (India)) (submittedVersion)
- Funders
- European Commission
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale (U1016)
- Association Française pour l'Etude du Foie (AFEF-2008)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- ChREBP, carbohydrate-responsive element-binding protein, hepatic steatosis, insulin resistance, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, lipogenesis, fatty acid esterification, stearoyl-CoA desaturase 1, monounsaturated fatty acids, Akt phosphorylation, insulin signaling, glucose tolerance, high-fat diet, lipidomics, hepatocytes
- MeSH terms
- Animals, Fatty Acids, Monounsaturated, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Nuclear Proteins, Phosphorylation, Stearoyl-CoA Desaturase, Transcription Factors, Metabolic Syndrome, Lipogenesis, Proto-Oncogene Proteins c-akt, Mice, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.